ERBB2 and breast carcinoma: The present findings offer the first evidence of the effectiveness of an LXR agonist in a stringent transgenic model of breast cancer fibrosis, and suggests a rationale for a new therapeutic approach to enhance the efficacy of therapies for HER2+ breast cancer and other malignancies.